Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).

Autor: Richeldi L; Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy luca.richeldi@policlinicogemelli.it., Azuma A; Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan.; Respiratory Medicine and Clinical Research Centre, Meisei Hospital, Saitama, Japan., Cottin V; Hôpital Louis Pradel, Centre Coordonnateur National de référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754, INRAE, Université Claude Bernard Lyon 1, Member of ERN-LUNG, Lyon, France., Kreuter M; Centre for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, German Center for Lung Research, Heidelberg, Germany.; Department of Pneumology, RKH Clinic Ludwigsburg, Ludwigsburg, Germany., Maher TM; Department of Pulmonary, Critical Care and Sleep Medicine, USC Keck School of Medicine, Los Angeles, California, USA.; Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK., Martinez FJ; Department of Medicine, Cornell University, New York City, New York, USA., Oldham JM; Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA., Valenzuela C; ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain., Gordat M; Clinical Development & Operation Department, Boehringer Ingelheim, Reims, France., Liu Y; Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Stowasser S; TA Inflammation Med, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Zoz DF; Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Wijsenbeek MS; Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Publikováno v: BMJ open respiratory research [BMJ Open Respir Res] 2023 Aug; Vol. 10 (1).

WS06-6 The inhaled epithelial sodium channel (ENaC) inhibitor BI 443651 is safe and well tolerated in adult patients with cystic fibrosis

Autor: Elborn, S., Singh, D., Fischer, R., Kornmann, O., Schwarz, C., Mall, M., Horsley, A., Gordat, M., Endriss, V., Risse, F., Iacono, P.

Publikováno v: In Journal of Cystic Fibrosis June 2019 18 Supplement 1:S12-S12

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Autor: Groop PH; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.; Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Baker IDI Heart and Diabetes Institute, Melbourne, Australia., Cooper ME; Baker IDI Heart and Diabetes Institute, Melbourne, Australia., Perkovic V; The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney, Australia., Hocher B; Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.; Department of Histology and Embryology, Medical College, Jinan University, Guangzhou, China.; IFLb, Institut für Laboratoriumsmedizin Berlin GmbH, Berlin, Germany., Kanasaki K; Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa, Japan.; Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Kanazawa, Japan., Haneda M; Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan., Schernthaner G; Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria., Sharma K; Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego, California., Stanton RC; Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts., Toto R; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas., Cescutti J; Boehringer Ingelheim France S.A.S, Reims, France., Gordat M; Boehringer Ingelheim France S.A.S, Reims, France., Meinicke T; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Koitka-Weber A; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Thiemann S; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., von Eynatten M; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Nov; Vol. 19 (11), pp. 1610-1619. Date of Electronic Publication: 2017 Jul 31.

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.

Autor: Groop PH; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia per-henrik.groop@helsinki.fi., Cooper ME; Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia., Perkovic V; The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia., Sharma K; Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, CA, USA Center for Renal Translational Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Schernthaner G; Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria., Haneda M; Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan., Hocher B; Institute of Nutritional Science, University of Potsdam, Potsdam, Germany., Gordat M; Boehringer Ingelheim, Reims, France., Cescutti J; Boehringer Ingelheim, Reims, France., Woerle HJ; Boehringer Ingelheim, Ingelheim, Germany., von Eynatten M; Boehringer Ingelheim, Ingelheim, Germany.

Publikováno v: Diabetes & vascular disease research [Diab Vasc Dis Res] 2015 Nov; Vol. 12 (6), pp. 455-62. Date of Electronic Publication: 2015 Jul 28.

Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022.

Autor: Tatsuhiko Urakami¹ urakami.tatsuhiko@nihon-u.ac.jp

Publikováno v: Clinical Pediatric Endocrinology. Jul2023, Vol. 32 Issue 3, p125-136. 12p.